Skip to main content

Bolt Biotherapeutics, Inc.

BOLT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001641281

In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Bolt Biotherapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of BOLT: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders7262−10
Shares35.5M33.6M−1.90M (−5.4%)
Value$449.1M$164.6M−$284.4M (−63.3%)

New holders (10)

Institutions that held Bolt Biotherapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to BOLT in Q4 2021
InstitutionSharesValue% of portfolio
Hawkeye Capital Management, LLC168,000$823.0K0.33%
HRT Financial LP51,582$252.0K0.00%
Manteio Capital LLC26,360$129.0K0.17%
Two Sigma Investments, LP25,500$125.0K0.00%
Jump Financial, LLC16,400$80.0K0.01%
Squarepoint Ops LLC14,138$69.0K0.00%
XTX Topco Ltd12,453$61.0K0.03%
Credit Suisse AG10,655$52.0K0.00%
ProShare Advisors LLC10,249$50.0K0.00%
TAP Consulting, LLC19$00.00%

Sold out (20)

Institutions that held Bolt Biotherapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.